Researchers at the Icahn School of Medicine at Mount Sinai reported IL‑12‑producing CAR T cells that directly target tumor‑associated macrophages (TAMs) and reset the immunosuppressive tumor microenvironment, increasing survival in aggressive preclinical models of metastatic ovarian and lung cancer. The work, published in Cancer Cell, demonstrated tumor control by disarming TAMs and enabling endogenous immunity. A complementary "Trojan horse" approach encoded proinflammatory genes into CAR T cells to improve efficacy without severe systemic toxicity. These studies position myeloid‑directed, armored CAR T as a potential strategy to extend cell therapy into solid tumors.